Log In

NeuroRx, Inc.

NeuroRx, Inc. is a clinical stage pharmaceutical company that is developing Cyclurad™, the first oral therapeutic for the treatment of suicidal crisis associated with bipolar disorder. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific.

NeuroRx’s investigational treatment approach begins with a single dose of ketamine, an FDA approved anesthetic, followed by approximately six weeks of daily oral Cyclurad. Cyclurad is being developed as a rapid-onset and sustained treatment for acute suicidal crisis associated with bipolar depression. Cyclurad combines D-cycloserine, an N-methyl-D-aspartate (NMDA) receptor modulator; and lurasidone, a 5-HT2a receptor antagonist.

Peer-reviewed and published results from two Phase II clinical studies demonstrate a significant decline in symptoms of depression and suicidality following administration of D-cycloserine. Findings from one of these studies found that bipolar patients who were already receiving a 5-HT2a antagonist demonstrated more than a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation when ketamine and D-cycloserine were added to their treatment regimen.